Show Policies

You understand that the World Health Organization and Centers for Disease Control and Prevention have classified COVID-19 as a highly contagious disease that can be transmitted asymptomatically and can lead to severe illness or death. You recognize that an inherent risk of exposure to COVID-19 and other infectious illnesses exists in any public place where people are present. You agree to abide by all policies and protocols established by AVIXA at InfoComm 2025 including but not limited to health and safety protocols implemented to minimize the spread of COVID-19. You understand that AVIXA, in its sole discretion, reserves the right to terminate your access to InfoComm 2025 without any refunds, in the event that you do not follow all protocols established or required by AVIXA.  

You also understand that AVIXA cannot eliminate the risk of you contracting COVID-19 or any other infectious illness in connection with your participation in InfoComm 2025. By attending InfoComm 2025, you voluntarily assume all known and unknown risks related to exposure to COVID-19 and other infectious illnesses and all risk of personal injury, illness, death, damage, and expense related to your participation in, and travel to and from, InfoComm 2025. 

In consideration of the opportunity to participate in InfoComm 2025 provided by AVIXA, Inc., you hereby FOREVER RELEASE, WAIVE, AND HOLD HARMLESS AVIXA, INC. AND ITS OFFICERS, DIRECTORS, EMPLOYEES, MEMBERS, VOLUNTEERS, REPRESENTATIVES, AND AGENTS from any and all liability, injury, damage, loss, or expense that may arise, directly or indirectly, now or in the future, regardless of whether caused by negligence or fault on the part of AVIXA, in connection with your participation in InfoComm 2025. 

You understand that this release and waiver is intended to be as broad and inclusive as is permitted by law, and that if any portion of this release and waiver is held invalid, the remainder will continue in full legal force and effect. This release and waiver will extend to, and be binding upon, you and your estate, heirs, executors, administrators, and personal representatives.  

You also certify that you have not tested positive for COVID-19 in the five (5) days prior to attending InfoComm 2025. In the spirit of minimizing the potential for the spread of disease through contact with individuals positive for COVID-19, AVIXA encourages  you to take a COVID-19 test prior to attending InfoComm 2025 if you are currently experiencing any symptoms associated with COVID-19, which may include cough, shortness of breath or difficulty breathing, fever, chills, congestion or runny nose, nausea or vomiting, diarrhea, fatigue, muscle or body aches, headache, sore throat, and/or new loss of taste or smell.   

If you have any questions or concerns about InfoComm’s COVID policies, please contact membership@avixa.org. 

• Membership purchased/upgraded through registration is not refundable. If you have questions on  membership, please contact membership@avixa.org. 

• All registration refund/cancellation requests must be submitted in writing to infocomm@compusystems.com. 

• A full refund will be issued for registration cancellations if written notice is received by May 7, 2025. 

• No refunds will be made for requests received after May 7, 2025. 

In the event that InfoComm 2025 fails to take place for any reason, including but not limited to cancellation by AVIXA due to an act of God, epidemic, pandemic, or other declared health emergency, emergency declared by any government agency, or for any other reason, the sole liability of AVIXA will be to provide a refund to you for the InfoComm 2025 registration fees you paid to AVIXA.  

This statement applies to speakers, staff, volunteers, guests, members, contractors, exhibitors, government participants and attendees.  

AVIXA, the owner of InfoComm, is committed to providing a professional environment free from physical, psychological and verbal harassment. AVIXA will not tolerate harassment of any kind, including but not limited to harassment based on age, ancestry, color, ethnicity, religion, citizenship, disability, familial status, marital status, registered domestic partner status, genetic information, physical appearance, gender, sex or sexual orientation, military and veteran status, or any other status protected by state, federal, and/or local law. This policy applies to all participants and attendees at AVIXA conferences, meetings and events. Harassment includes but is not limited to offensive gestures and verbal comments, deliberate intimidation, stalking, following, inappropriate photography and recording, sustained disruption of talks or other events, inappropriate physical contact, and unwelcome attention. Participants requested to cease harassing behavior are expected to comply immediately, and failure to comply will serve as grounds for revoking access to the AVIXA event and other consequences as determined appropriate by AVIXA in its sole discretion. 

Attendees, speakers, staff, volunteers, guests, members, and contractors are encouraged, but not required, to inform any person who engaged in harassing behavior that their conduct is unwelcome and should cease. Regardless of whether the harasser is directly confronted, speakers, staff, volunteers, guests, members, contractors, attendees are encouraged to promptly report the conduct to AVIXA event management or any on-site AVIXA management, to enable AVIXA to investigate and address the conduct.  AVIXA staff will be available to help participants contact convention center/hotel/venue security or local law enforcement as appropriate, and otherwise assist those experiencing harassment to enable them to feel safe for the duration of the event. 

When notified of individuals engaging in harassing behavior, AVIXA may take any action they deem appropriate, ranging from a simple warning to expulsion from the current and/or future AVIXA meetings, conferences, and events, and suspension or revocation of membership in AVIXA. Decisions to ban individuals from future AVIXA events is in the sole discretion of AVIXA.